Abstract Human pluripotent stem cells hold great promise for basic research and regenerative medicine due to their inherent property to propagate infinitely, while maintaining the potential to differentiate into any given cell type of the human body. Since the first derivation in 1998, pluripotent human embryonic stem cells (ESCs) have been studied intensively, and although these cells provoke ethical and immune rejection concerns, translation of human ESC research into the clinics has been initiated. The generation of embryonic stem cell-like human induced pluripotent stem cells (iPSCs) from somatic cells by virus-mediated overexpression of distinct sets of reprogramming factors (OCT4, SOX2, KLF4, and c-MYC, or OCT4, SOX2, NANOG, and LIN28) in 2007 has opened up further opportunities in the field. While circumventing the major disputes associated with human ESCs, iPSCs offer the same advantages and, in addition, new perspectives for personalized medicine. This review summarizes technical advances toward the generation of potentially clinically relevant human iPSCs. We also highlight key molecular events underlying the process of cellular reprogramming and discuss inherent features of iPSCs, including genome instability and epigenetic memory. Furthermore, we will give an overview of particular envisaged human iPSC applications and point out which improvements are yet to come and what has been achieved so far.
Introduction
Human pluripotent stem cells, which have the ability to selfrenew indefinitely and to form derivatives of all three embryonic germ layers, are of great value for basic research and potential applications in the clinics. Besides teratomaderived embryonal carcinoma cells and embryonic germ cells, biomedical research has focused on human embryonic stem cells (ESCs) as the gold standard of human pluripotent stem cells ever since their derivation by Thomson et al. in 1998 [1] . However, ethical as well as immune rejection concerns are two major issues associated with the utilization of human ESCs in basic and translational research. These conflicts were overcome with the groundbreaking achievement of generating human induced pluripotent stem cells (iPSCs), which are pluripotent stem cells derived from somatic cells mediated by the ectopic expression of four transcription factors, namely OCT4, SOX2, KLF4, and c-MYC [2] , or OCT4, SOX2, NANOG, and LIN28 [3] . This review briefly summarizes the recent technical progress that has been made regarding the generation of human iPSCs, highlights key molecular mechanisms underlying and associated with the process of cellular reprogramming, and illustrates areas of potential applications of human iPSCs emphasizing their value for personalized medicine ( Fig. 1 ).
Generation and mechanisms

Techniques to generate human iPSCs
Since the first generation of human iPSCs, retro-or lentiviral overexpression of the reprogramming factors has proven to be a robust and efficient way of inducing pluripotency in somatic cells. Efforts have been made to reduce or avoid integration of foreign DNA into the target cells' genomes in order to minimize unpredictable effects of random integrations. To this end, both the identification of small molecules, which enhance the efficiency of cellular reprogramming, and the use of different somatic cell types at distinct developmental stages as starting material have facilitated the reduction of the number of integrating vectors required to induce pluripotency. Valproic acid (VPA), a histone deacetylase inhibitor, for instance, has been shown to increase the efficiency of three factor-mediated reprogramming (OCT4, SOX2, KLF4) and facilitated the generation of human iPSCs by only two factors, namely OCT4 and SOX2 [4] . Furthermore, VPA in combination with 8-bromoadenosine 3′, 5′-cyclic monophosphate , an analog of cyclic AMP, enhanced the induction of pluripotency in human fibroblast cells [5] . Interestingly, vitamin C also mediated the generation of human iPSCs with greater efficiency [6] . Similarly, combined small molecule-based modification of distinct signaling pathways involved in the reprogramming process has been shown to greatly increase the efficiency of reprogramming using fewer reprogramming factors on distinct cell types. This is particularly interesting as supplementation with single molecules may not be Fig. 1 Hallmarks of cellular reprogramming and applications of human iPSCs. Somatic cells obtained from any given donor can be reprogrammed to iPSCs using a number of different techniques. Key molecular events that mark this de-differentiation process include global chromatin remodeling, circumvention of p53-induced cell cycle arrest, reprogramming of mitochondria and, in close context, the energy metabolism toward increased glycolysis and decreased mitochondrial oxidative phosphorylation (OXPHOS), and the process of mesenchymal-to-epithelial transition (MET). Once human iPSCs lines from healthy or diseased individuals have been established and fully characterized, they offer unprecedented opportunities in personalized regenerative medicine. Human iPSCs are valuable tools for studying early developmental processes, to model human diseases in a dish, thereby enabling the identification of new diagnostic markers and tools and potential new drug targets, and to perform large-scale toxicity and drug screens upon differentiation into other appropriate cell types. Eventually, human iPSCs are envisaged to directly treat a particular condition of the donor through cellular replacement therapy, if needed, by transplantation of genetically corrected autologous cells as efficient as the simultaneous addition of several chemicals [7] . To this end, transient treatment with defined cocktails including, for instance, the ALK4/5/7 inhibitors SB431542 and A-83-01, the MEK inhibitor PD0325901, the GSK-3 inhibitor CHIR99021, the inhibitor of lysine-specific demethylase 1 Parnate (also known as tranylcypromine), the allosteric activator of 3′-phosphoinositide-dependent kinase-1 (PDK1) PS48, the histone deacetylase inhibitor sodium butyrate (NaB), thiazovivin, p160 Rho-associated coiled-coil kinase (ROCK) inhibitor HA-100, and human leukemia inhibitory factor could enhance distinct reprogramming protocols in various somatic cell types, e.g., induction of pluripotency in keratinocytes by overexpression of only OCT4 [7] [8] [9] [10] . An alternative approach for reducing the number of genomic integrations includes the development of single vectors, which encode all necessary reprogramming factors and that could potentially be excised from the iPSCs' genomes following acquisition of the fully reprogrammed embryonic stem cell-like state [11] [12] [13] [14] . To date, the generation of genetically unmodified human iPSCs has been mediated by transduction of non-integrating adenoviruses [15] or RNA-based Sendai viruses [16] , repeated transfection of expression plasmids [17] or repeated electroporation of episomal plasmids [9, 18] or so-called mini circle DNA [19] , all of which encode the required reprogramming factors. In contrast to these approaches, Kim et al. treated neonatal fibroblasts with recombinant versions of the reprogramming factor proteins to induce pluripotency [20] ; however, this approach was very inefficient. The most recent strategies to de-differentiate human somatic cells included repeated transfection of reprogramming factor-encoding, synthetically modified mRNAs [21] and overexpression of human embryonic stem cell-specific miRNAs, either by lentiviral transduction [22] or by transfection of cocktails of mature miRNAs [23] . However, reproducing studies have yet to be published. A critical review of the in vitro derived mRNA-based reprogramming protocol has revealed major obstacles that need to be addressed before this technique becomes routinely applicable for successful cellular reprogramming [24] .
As a result of the combined efforts to efficiently generate pluripotent cells, while avoiding genomic alterations, a wide range of human somatic cells have been reprogrammed, including melanocytes [25] ; cord blood-derived cells [9, 26, 27] ; adult peripheral blood cells [26, 28, 29] ; cells obtained from adipose tissue [6, 9, 23, 30] ; hepatocytes [31] , and amniotic fluid [10, [32] [33] [34] ; and chorionic villi-derived cells [34] amongst others.
Molecular events underlying cellular reprogramming
Despite a basic understanding of the OCT4, SOX2, NANOG-regulated transcriptional regulatory network that shapes the undifferentiated human pluripotent stem cell identity [35] [36] [37] , our knowledge of distinct pathways and mechanisms involved in the conversion of the somatic into the pluripotent phenotype is limited. We, therefore, in a recent study analyzed early events triggered by retroviral transduction of the reprogramming factors OCT4, SOX2, KLF4, and c-MYC-the original method that has proven to be very robust with respect to inducing pluripotency in somatic cells. One of the key findings was that, levels of reactive oxygen species (ROS) increased significantly upon viral transduction, leading to DNA damage and ultimately to the activation of p53, which is responsible for arresting cell cycle and inducing apoptosis and senescence. Hence, we found transcripts involved in apoptosis, cell cycle regulation, and aging to be over-represented [38] . These findings are in line with the observations that direct or indirect, stable or transient downregulation of p53 enhances cellular reprogramming in mouse and human somatic cells [5, [39] [40] [41] [42] [43] [44] . Hence, overcoming this hurdle is a crucial step in acquiring a pluripotent state.
Furthermore, suppression of the epithelial-to-mesenchymal transition and promotion of the reverse process, the mesenchymal-to-epithelial transition (MET), have been shown to be another critical step in the process of cellular reprogramming of mouse cells of mesenchyme origin [45] [46] [47] . Likewise, in a meta-analysis, we identified the initiation of MET as an early reprogramming event in human fibroblasts [38] eventually resulting in the establishment of the epithelial ESC-like phenotype characterized by multiple cell-cell adhesion complexes [48] [49] [50] . This is also supported by the ameliorating effect of TGFβ pathway and GSK3 inhibitors on cellular reprogramming [7] [8] [9] [10] .
Especially in order to enable access of the transcription machinery to pluripotency-associated genes and, thus, for the major transcriptional changes to occur in the process of reprogramming, epigenetic remodeling through distinct alteration of histone modification and CpG methylation patterns is required as highlighted in the first report of human iPSCs [2] . Global studies based on mouse embryonic fibroblasts (MEFs) and MEF-derived iPSCs unveiled greater details about the kinetics of distinct histone modifications that occur throughout the de-differentiation process [51] . Again, these findings are in line with the observation that treatment of somatic cells with agents, which influence the chromatin remodeling machinery, such as VPA, sodium butyrate, or vitamin C, following overexpression of the reprogramming factors increases reprogramming efficiencies [4, 6, 10] .
Reprogramming of mitochondria and energy metabolism Reprogramming of energy metabolism is a known feature of cancer cells [52] . As cancer cells proliferate, there appears to be a switch from mitochondrial-based oxidative phosphorylation to glycolysis even in the presence of oxygen, a phenomenon referred to as the Warburg effect [53] . This was initially thought to be due to damage to mitochondria while more recent findings suggest that the reason for this switch lies in the change of energy requirement and anabolic demands of tumor cells [54] . In fact, cancer cells exhibit a high necessity of building the macromolecules needed to proliferate while avoiding the generation of high levels of ROS, a common by-product of mitochondrial respiration. Hence, cancer cells opt for re-routing the energy flux outside the organelle.
A similar mechanism may also be in place during reprogramming. Recent findings from our group [55, 56] and from others [10, [57] [58] [59] [60] [61] [62] suggest, indeed, that the derivation of iPSCs is associated with a reconfiguration of mitochondria and bioenergetic metabolism. Mitochondria within iPSCs exhibit a reduction in number [55, 57, 59 , 60] and oxidative phosphorylation, which then translates into increased glycolysis [55, 56, 58, 61, 62] and lower production of ROS [55, 57, 63] . Interestingly, these metabolic changes may play an instrumental role in reprogramming, as they occur before the re-establishment of the human ESC-like properties [58] . Accordingly, the modulation of oxygen levels and the small molecule-based alteration of energy metabolism have been found capable of significantly enhancing the efficiency of cellular reprogramming [10, 64] .
Genomic instability
Recent findings have pointed out that the derivation of iPSCs alters the integrity of the genomes of the parental cells. The occurrence of chromosomal aberrations within human ESCs and iPSCs has been demonstrated by different groups [65, 66] , as the reprogramming process has been found to be associated with a high mutation rate [67] [68] [69] . Certain types of aneuploidies within human ESCs and iPSCs may induce proliferative advantage by increasing the expression of pluripotency-associated genes. Accordingly, the affected chromosomes have been found to harbor genes such as NANOG, LIN28, or LEFTY [65, 66] . Additionally, we recently demonstrated that the mitochondrial genome might also undergo mutational events [63] . This is a highly relevant issue as genome integrity is of critical importance for iPSC-based clinical applications. Hence, it is essential to address the biological and clinical relevance of these mutations. Reassuringly, the detected chromosomal abnormalities have so far not been linked with a functional defect. Indeed, genomic aberrations have been suggested to be transient as they do not compromise cellular functionality [69] . It has also been demonstrated that several iPSC lines harboring karyotype variations could pass a stringent test of differentiation capacity [70] . In accordance, we observed that, although aged-derived iPSCs exhibited numerous chromosomal aberrations, the cells showed low levels of oxidative stress and DNA damage, in a similar manner as iPSCs derived from young donors and human ESCs, and did not exhibit apoptosis resistance, which are all hallmarks of cancer transformation [63] . Finally, the presence of mitochondrial mutational events did not affect the reprogramming-associated modulation of mitochondria and energy metabolism [56] .
Taken together, despite the potential risks for iPSC-based clinical applications, the detected loss of nuclear and mitochondrial genome integrity has not been associated with any specific cellular deficiency, suggesting that reprogrammingrelated genomic alterations might not necessarily translate in the acquirement of malignant features. Nevertheless, further in-depth investigations are warranted to distinguish harmless variations from those impairing the functionality or promoting clinical risks [71] .
Epigenetic memory
With the progress of the iPSC field, an increasing number of human and murine somatic cell types have been reprogrammed to a pluripotent state enabling studies to evaluate basic pluripotent stem cell properties among iPSCs derived from different origins and by different techniques and also with respect to human ESCs. One of the early, comparative studies of that kind was based on global gene expression, miRNA expression, and histone modification data, amongst others; this revealed that distinct molecular signatures are characteristic for iPSCs from certain tissues of origin (although derived from different species) and distinguished iPSCs from ESCs [72] . Kim et al. were able to identify and link DNA methylation patterns of murine and human iPSCs from different tissues to their characteristic differentiation behavior but noticed diminution of these marks, at least in mouse iPSCs, by repeated rounds of reprogramming and chromatin-modifying chemicals [73, 74] . Similarly, Polo et al. were able to correlate patterns of chromatin modification with distinct expression signatures and differentiation properties using a system of mouse so-called secondary iPSCs [75] . For human iPSCs, different reports have highlighted the existence of residual gene expression patterns in distinct iPSCs, which may result from incomplete promoter DNA methylation of tissue-specific genes and which also distinguish them from human ESCs, even if non-integrating reprogramming methods were used; it was also shown that these iPSCs preferably differentiate back into the lineage they were originally derived from [31, 33, [76] [77] [78] . This inherent characteristic of iPSCs can be exploited in the sense that if donor cells of mesoderm origin (e.g., cardiomyocytes and adipocytes) are needed for downstream applications, one should use cells of mesoderm origin (bone marrow-derived MSCs) as the source for reprogramming into iPSCs. A precedence for this is the derivation of iPSCs from retinal pigmented cells and the rapid and efficient differentiation of these back to the original cell type [77] .
In contrast, Guenther et al. argued against the existence of an epigenetic memory following a meta-analysis of transcriptional and histone modification data [79] . They suggested that the slight differences observed were primarily due to laboratory-specific bias rather than fundamental differences between different types of human iPSCs and iPSCs and ESCs. In summary, the question if iPSCs retain an epigenetic memory throughout the process of de-differentiation and whether they are to be distinguished from human ESCs as a separate pluripotent cell type is still a matter of debate, which will be clarified as research proceeds.
Clinical applications
Modeling human diseases in a dish
The successful conversion of human fibroblasts into induced pluripotent stem cells has opened up new opportunities for modeling human diseases. The iPSC technology has provided a unique possibility to investigate molecular mechanisms underlying the etiology of many diseases in vitro.
Within the last few years, several disease models have been generated and affirmed that iPSCs enable to reconstruct a disease phenotype in vitro. In Table 1 , we present a list of selected published disease models, for which iPSCderived somatic cells have been shown to possess the disease phenotype or which have been used for drug screens or other functional studies. Definitely, it is a very demanding task to indeed prove that the models convey the features of the disease. It is necessary to recruit a reasonable amount of patients, generate many iPSC lines, and efficiently differentiate iPSCs into the disease-affected cell type. However, it is worthwhile, because once generated, "disease in a dish" provides an extraordinary opportunity to find novel diagnostic markers and tools, to identify drug targets, and to screen for novel compounds that can treat the disease of interest. For several disease models including spinal muscular atrophy (SMA) [80] and Rett's syndrome [81] , it has been successfully demonstrated that in vitro drug treatment restores normal distribution of affected protein.
Human iPSCs as a tool for toxicology studies
The main funds of pharmaceutical companies are spent on screening for metabolic properties early in drug discovery processes [82] . The implementation of human iPSCs will significantly simplify this procedure as unpredicted human metabolism is one of the main causes of the withdrawal of potential new drugs from pharmaceutical projects. Principally, any cell type existing today does not copy the complexity and function of the liver. The human models available to date are utilizing cancer cell lines or primary cells isolated from liver biopsies; unfortunately, these two cell types possess significant limitations [83, 84] . Primary human hepatocytes are currently used as the gold standard in drug metabolism studies even though they lose functional properties when maintained in vitro. In general, there is an immense requirement for in vitro models of healthy and disease-specific hepatocytes. Hepatocytes and cardiomyocytes are the most susceptible to drug-induced damage (toxicity). It is very difficult to precisely predict hepatotoxic and cardiotoxic properties of new compounds in humans, and in many cases, toxicity is observed only in the late phases of clinical trials, due to the species-specific differences and extensive use of animal models. Although significant progress has been made in differentiating iPSCs cells into cardiomyocytes [85, 86] and hepatocytes [87] [88] [89] [90] , still, efficient generation of a pure and mature cell population has not yet been accomplished. Undoubtedly, the standardization of the production of functional human cells is needed, only then iPSC-derived hepatocytes, cardiomyocytes, neurons, and other cell types will significantly improve the in vitro metabolism studies and toxicity trials.
Therapeutic potential of human iPSCs
The generation of patient-specific pluripotent stem cells has been one of the major goals in the field of regenerative medicine. Differentiation of iPSCs into a distinct cell types is of prime importance, simply because access to a large number of cells would allow their use instead of whole organ transplantation. As iPSCs are explored as a source for generating unlimited amounts of patient-specific cells for transplantation, it is very important to precisely understand the developmental processes that guide the maturation of the specific cell fate and, thereby, help to repeat these events in vitro and engineer artificial cells and tissues. In theory, human iPSCs could be applied to treat a wide range of human diseases.
The in vitro developmental potential and the success of iPSCs in animal models [91, 92] reveal the principle of using human iPSC-derived cells as a regenerative source for transplantation therapies. In this respect, the first clinical trials using human ESC-derived cells will lay the foundation for future clinical applications of iPSCs. Recently, the company Advanced Cell Technology undertook a cell replacement trial to assess the safety of treating macular dystrophy by transplantation of human ESC-derived retinal pigment cells [93] . Despite the initial success in this trial, the "cows are yet to come home," and most importantly, it is too soon to exclude the emergence of long-term effects in these patients. Despite this hopeful human ESCs-based trial in the eye, which is an immune-privileged organ, many general and experimental obstacles must be solved before specified cell types derived from iPSCs can be applied to humans. First, provision of personalized medicine in the form of patient-specific iPSC-derived cellular therapeutics is very promising but costly. To compromise on time and high costs for the generation, characterization, and safety validation of individual clinical-grade iPSC lines on the one hand and possible immune rejection of non-autologous transplants on the other, the establishment of HLA-haplotype banks of iPSCs has been suggested [94, 95] . Associated with that, however, are the low cloning efficiency and poor survival of human pluripotent stem cells following cryopreservation [96] . Although an improvement of both aspects has been reported for the supplementation of culture media with ROCK inhibitors, such as Y-27632 [97] [98] [99] , there is room for further optimization of pluripotent stem cell cryopreservation protocols. Second, standards of defined, xeno-free human iPSC culture, differentiation, and cryopreservation conditions, i.e., feeder-free culture or maintenance on autologous feeders [100] in media devoid of non-human components, have to be uniformly applied [101, 102] . Third, it is crucial that we develop an efficient alternative approach to viral reprogramming and to understanding the genetic and epigenetic changes that take place during this process. Furthermore, the risk of teratoma formation, toxicity, and immunological rejection should be eliminated. Moreover, protocols for efficient and reproducible derivation of fully matured cells from iPSCs and purification of defined cell lineages should be optimized.
In summary, although hurdles remain to be overcome before the iPSC technology can be routinely applied in in vitro disease studies, drug development, toxicity tests, and cellular replacement therapies, major progress has been made. Generally, technologies to derive footprint-free human iPSCs have been established. Numerous diseasespecific iPSC lines have been derived, and differentiation protocols to generate terminally differentiated cells of interest have been developed. CELLular Dynamics International, for example, set new standards offering a variety of iPSCderived terminally differentiated cell types, e.g., cardiomyocytes, hepatocytes, and neuronal cells, which are useful for studying molecular mechanisms underlying distinct diseases, assessing safety and efficacy of potential new drugs, and evaluating toxicity in vitro [103] [104] [105] . Furthermore, a lot will be learned from the first ongoing and proposed clinical trials involving human ESC-derived cell products, which will be transferable to human iPSCs in the future.
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